Received Jul 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Arexvy administered to pregnant women; healthcare system decided to switch from Arexvy to Abrysvo due to some instances where Arexvy was administered to pregnant women; This non-serious prospective pregnancy case was reported by a other health professional via sales rep and described the occurrence of vaccine exposure during pregnancy in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received the 1st dose of Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced vaccine exposure during pregnancy (Verbatim: Arexvy administered to pregnant women) and product use in unapproved population (Verbatim: healthcare system decided to switch from Arexvy to Abrysvo due to some instances where Arexvy was administered to pregnant women). The outcome of the vaccine exposure during pregnancy and product use in unapproved population were not applicable. Pregnancy exposure: Pregnancy Exposure (Arexvy): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 16-JUL-2025 The health care professional reported that the Arexvy vaccine administered to pregnant women, which led to vaccine exposure during pregnancy and contraindicated product administered. The healthcare system decided to switch from Arexvy to Abrysvo due to some instances where Arexvy was administered to pregnant women. She had no other details about these administrations.